Abiraterone Precursor Prodrug for Higher Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for prostate cancer, such as castration therapies, fail to inhibit androgen biosynthesis in adrenal glands and other tissues, allowing the cancer to continue growing, necessitating a more effective CYP17 inhibitor.
Innovation Solution
Development of a novel abiraterone precursor compound and its pharmaceutically acceptable salts, synthesized through specific reactions and solvent systems, which can be rapidly absorbed and degraded into the active ingredient abiraterone, enhancing bioavailability and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If castration therapy is used to inhibit androgen biosynthesis, then testosterone production in testes is reduced, but androgen biosynthesis in adrenal glands and other tissues remains unaffected
Solution Approach 1:
The CYP17 inhibitor is designed to perform multiple functions simultaneously: it inhibits androgen biosynthesis in testes, adrenal glands, and other tissues containing CYP17 enzyme. This multi-tissue inhibition capability resolves the contradiction by making the treatment universally effective across all androgen-producing sites, not just the testes as with castration therapy.
2Reliability
If abiraterone acetate is administered, then CYP17 inhibition is achieved, but bioavailability and plasma concentration are limited
Solution Approach 1:
The patent modifies the chemical structure of abiraterone by creating prodrug derivatives with different physicochemical parameters. These structural changes improve solubility, stability, and absorption characteristics, thereby increasing bioavailability and plasma concentration while maintaining the core CYP17 inhibition mechanism.
3Quantity of substance
If novel precursor compounds are developed, then bioavailability and plasma concentration are improved, but synthesis complexity increases
Solution Approach 1:
The patent designs prodrug compounds that are pre-modified with specific chemical groups to enhance bioavailability. These preliminary structural modifications are strategically planned to enable simple, one-step or two-step synthesis routes from existing abiraterone, avoiding complex multi-step processes while achieving improved pharmacokinetic properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The abiraterone precursor compound demonstrates superior bioavailability, higher plasma concentration, and improved therapeutic effects compared to abiraterone acetate, with enhanced safety and efficacy in inhibiting androgen biosynthesis.
Implementation Method 1
the abiraterone precursor compound is a novel compound, which is comparable to abiraterone acetate and even superior to abiraterone acetate in some aspects. Therefore, the abiraterone precursor compound has a great market value.
Data Source
AI summary
A precursor compound of abiraterone, and a preparation method and use thereof are provided. The compound has a structure represented by a formula I. The present disclosure also provides a preparation method of the compound represented by the formula I, a hydrochloride salt of the compound represented by the formula I and a preparation method thereof, and uses of the compound and the hydrochloride salt in preparation of a 17α-hydroxylase/C17,20-lyase (CYP17) inhibitor drug.